UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 7, 2022

RELMADA THERAPEUTICS, INC.

(E.	xact name of registrant as specified in its charter)		
Nevada	001-39082	45-5401931	
(State or other jurisdiction	(Commission File Number)	(IRS Employer	_
of incorporation)		Identification No.)	
2222 Ponce de Leon Blvd, Floor 3			
Coral Gables, FL		33134	
(Address of principal executive offices)		(Zip Code)	

Registrant's telephone number, including area code +1-786-629-1376

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of exchange on which registered		
Common stock, \$0.001 par value per share	RLMD	The NASDAQ Stock Market LLC		

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

On March 7, 2022, Relmada Therapeutics, Inc., updated its corporate presentation, a copy of which is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Corporate Presentation dated March 7, 2022
104	Cover Page Interactive Data File (formatted as Inline XBRL)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RELMADA THERAPEUTICS, INC.

By:/s/ Sergio TraversaName:Sergio TraversaTitle:Chief Executive Officer



Targeting Major Advances in Treatment of CNS Disorders

March 7, 2022 | Nasdaq: RLMD

Disclosures

Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the "Company"), along with certain statements that may be made by management of the Company orally in presenting this material, may contain "forward-looking statements." These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as "estimate," "expect," "intend," "believe," "plan," "anticipate," "projected" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Statements regarding future action, future performance and/or future results, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA's or other regulatory review and/or approval and commercial launch and sales results (if any) of the Company's formulations and products and regulatory filings related to the same may differ from those set forth in the forward-looking statements. Peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such sales levels will be achieved, if at all, or that such market size estimates will prove accurate.

Because actual results are affected by these and other potential risks, contingencies and uncertainties, the Company cautions investors that actual results may differ materially from those expressed or implied in any forward-looking statement. It is not possible to predict or identify all such risks, contingencies and uncertainties. The Company identifies some of these factors in its Securities and Exchange Commission ("SEC") filings on Forms 10-K, 10-Q and 8-K, and investors are advised to consult the Company's filings for a more complete listing of risk factors, contingencies and uncertainties affecting the Company and its business and financial performance.

The Company assumes no obligation to update forward-looking statements as circumstances change. Investors are advised to consult further disclosures that the Company makes or has made on related subjects in the Company's Form 10-K, 10-Q and 8-K reports.

Investment Highlights

CNS Focus with Lead Program in Major Depressive Disorder (MDD)


Highly Compelling Opportunity in REL-1017

Multiple Catalysts Expected Over Next 18 Months


CNS= Central Nervous System **Our fiscal year end is December 31. The periods referred to in this slide are calendar years and quarters.



Major Depressive Disorder & REL-1017



Prevalence of Depression



Limitations of Current Treatments for MDD



even when effective, may

take up to 8 weeks to

reach efficacy1

Side effects of atypical antipsychotics approved as adjunctive treatments for MDD include tardive dyskinesia, metabolic syndrome, cognitive impairment and stroke²

treatment¹

MDD = major depressive disorder 1. Trivedi MH, et al. Am J Psychiatry. 2006;163:28-40; 2. Ashton AK, et al. Curr Ther Res. 2005;86(2):97-106; 2. US Prescribing information, brexpiprazole, quellapine, aripiprazole


respond to first antidepressant

Unique Profile of REL-1017

Potential as a rapid, oral, once-daily antidepressant for MDD, if approved

- Novel Mechanism of Action: preferential targeting of NMDAR channels potentially associated with MDD¹
- Available clinical data demonstrated:
 - Robust, rapid, and sustained statistically significant antidepressant effects on all tested scales²
 - Rapid onset: significant efficacy effects by Day 4²
 - Favorable safety and tolerability profile consistent across Phases 1 & 2 studies: no opioid and no psychotomimetic adverse events^{2,3} and no metabolic side effects
 - · Orally administered, once-daily tablet

MDD = major depressive disorder; NMDAR = N-methyl-D-aspartate receptor




7


The angle depresence desced, internet enternet enternet enternet and the angle of t



REL-1017 Ph 1 & 2 Efficacy & Safety Data



Phase 1 SAD & MAD Studies for REL-1017, Data Published 2019



PK = pharmacokinetics; PD = pharmacodynamics; MTD: =maximum tolerated dose; C_{max} = maximum plasma concentration; AUC_{Over} = area under the curve 0 to infinite time; AUC₁ = area under the curve to the end of dosing period; N = number of patients; NMDA = N-methyl-D-aspartate receptor antagonist; AESI = adverse event of special interest Source: Bernstein, G. et al., J. Clin. Psychopharmacology 2019 May/Jun; 39(3):226-237.


Phase 2 Study REL-1017: Primary Efficacy Endpoint

REL-1017 showed rapid and sustained differences in MADRS change vs. placebo



* P-value <.05

REL-1017 Phase 2 Study Efficacy: Response & Remission



Safety & Tolerability Findings from Phase 2

Safety & Tolerability Comparable to Placebo

- Only Mild and Moderate transient AEs no SAEs
- No increased prevalence of specifically relevant organ group AEs in treatment groups vs placebo
- No evidence of opiate effects or withdrawal symptoms in treatment groups vs placebo
- No evidence of treatment-induced dissociative or psychotomimetic symptoms in the treatment groups vs placebo

REL-1017 Phase 2 Study Safety: Treatment Emergent Adverse Events

Treatment-emergent adverse events by preferred term in patients with MDD in the safety analysis set*

Variable –	Placebo (N = 23)		REL-1017	REL-1017 25 mg (N=19)		REL-1017 50 mg (N=21)		All Patients (N = 62)	
variable	N	%	N	%	N	%	N	%	
Patients with a serious adverse event	0	0.0	0	0.0	0	0.0	0	0.0	
Patients with a severe treatment-emergent adverse event	0	0.0	0	0.0	0	0.0	0	0.0	
Patients with at least one adverse event	12	54.5	9	47.4	15	71.4	36	58.1	
Treatment-emergent adverse events occurring in three or more patients									
Constipation	3	13.6	1	5.3	3	14.3	7	11.3	
Nausea	2	9.1	1	5.3	2	9.5	5	8.1	
Diarrhea	3	13.6	0	0.0	0	0.0	3	4.8	
Headache	3	13.6	2	10.5	3	14.3	8	12.9	
Somnolence	2	9.1	1	5.3	1	4.8	4	6.5	
Dizziness	1	4.5	1	5.3	1	4.8	3	4.8	
Back Pain	0	0.0	1	5.3	2	9.5	3	4.8	


Source: Fava et al. 2021 American Journal of Psychiatry Treatment-emergent adverse event was defined as an adverse event that started or worsened after treatment with the trial drug

13

R

Human Abuse Potential (HAP) Studies:

REL-1017 vs. Oxycodone REL-1017 vs. Ketamine



Human Abuse Potential (HAP) Studies of REL-1017

HAP Studies, per FDA's Guidance for Industry1:

- Typically required for CNS-active drugs
- Should be conducted in experienced recreational drug users
- Should use standardized questionnaires at specific timepoints
- · Positive controls should be FDA-approved controlled substances pharmacologically similar to the test drug
- HAP studies are included in the New Drug Application (NDA) and used in determination of drug scheduling

The HAP Program for REL-1017 includes two studies:

- Mu Opioid Agonist HAP
 - Oxycodone as active control
 - Completed in July 2021
- NMDA Receptor Antagonist HAP
 - Ketamine as active control
 - Completed in February 2022

1 Assessment of Abuse Potential of Drugs Guidance for Industry 2017 https://www.fda.gov/media/116739/download

15

Primary Endpoint – "Drug Liking at This Moment" [Emax] REL-1017 vs. Oxycodone, Completer Population*

Statistic Parameter	Placebo	REL-1017 25 mg	REL-1017 75 mg	REL-1017 150 mg	Oxycodone 40 mg
n	47	47	47	47	47
Mean	52.7	54.2	58.7	64.9	83.2
Median	50	50	50	58	85
SD	6.52	10.35	15.82	16.58	16.57
SE	0.95	1.51	2.31	2.42	2.42

Consistent results were seen for the secondary endpoints

*Previously reported results for the oxycodone REL-1017-124 study analyzed the Modified Completer Population (44 subjects) instead of the Completer Population (47 patients)

Primary Endpoint – "Drug Liking at This Moment" [Emax] REL-1017 vs. Oxycodone, Completer Population*

Statistical Analysis

REL-1017 vs. Oxycodone

Treatment 1	Treatment 2	P-value
Oxycodone 40 mg	Placebo	<0.001
Oxycodone 40 mg	REL-1017 25 mg	<0.001
Oxycodone 40 mg	REL-1017 75 mg	<0.001
Oxycodone 40 mg	REL-1017 150 mg	<0.001

All REL-1017 doses are statistically different from oxycodone (p<.05)

REL-1017 vs. Placebo

Treatment 1	Treatment 2	P-value
REL-1017 25 mg	Placebo	<0.001
REL-1017 75 mg	Placebo	<0.001
REL-1017 150 mg	Placebo	<0.05

All REL-1017 doses are statistically equivalent to placebo (p<0.05)

* Previously reported results for the oxycodone REL-1017-124 study analyzed the Modified Completer Population (44 subjects) instead of the Completer Population (47 patients)

SD = Standard Deviation;	SE = Standard Error
Source: Reimada data on	file.

Human Abuse Potential (HAP) Studies of REL-1017 vs. Oxycodone Primary endpoint, Drug Liking (Emax) Completer Population*

- All REL-1017 doses including 150 mg (6x therapeutic dose and MTD) were statistically different from oxycodone 40 mg (p<0.05)
- All REL-1017 doses including 150 mg (6x therapeutic dose and MTD) were statistically equivalent to placebo (p<0.05)
- Key secondary endpoint results were consistent with primary endpoint

*Statistical analysis were performed on the Completer Population which includes all patients who completed all treatments. Previously reported results for the oxycodone REL-1017-124 study analyzed the Modified Completer Population (44 subjects) instead of the Completer Population (47 patients).

Primary Endpoint – "Drug Liking at This Moment" [Emax] REL-1017 vs. IV Ketamine, Completer Population

Statistic Parameter	Placebo	REL-1017 25 mg	REL-1017 75 mg	REL-1017 150 mg	Dextromethorphan 300 mg	Ketamine 0.5mg/Kg
n	51	51	51	51	51	51
Mean	50.9	51.4	54.9	59.2	68.4	90
Median	50	50	50	51	60	100
SD	2.23	3.28	9.58	14.38	18.39	14.52
SE	0.31	0.46	1.34	2.01	2.57	2.03

Consistent results were seen for the secondary endpoints

19

Primary Endpoint – "Drug Liking at This Moment" [Emax] REL-1017 vs. IV Ketamine, Completer Population

Statistical Analysis

REL-1017 vs. IV Ketamine

Treatment 1	Treatment 2	P-value
Ketamine 0.5 mg/ Kg	Placebo	<0.001
Ketamine 0.5 mg/ Kg	REL-1017 25 mg	<0.001
Ketamine 0.5 mg/ Kg	REL-1017 75 mg	<0.001
Ketamine 0.5 mg/ Kg	REL-1017 150 mg	<0.001

All REL-1017 doses are statistically different from ketamine (p<0.05)

REL-1017 vs. Placebo

Treatment 1	Treatment 2	P-value
REL-1017 25 mg	Placebo	<0.001
REL-1017 75 mg	Placebo	<0.001
REL-1017 150 mg	Placebo	0.003

All REL-1017 doses are statistically equivalent to placebo (p<0.05)

Human Abuse Potential (HAP) Studies of REL-1017 vs. IV Ketamine, Primary endpoint, Drug Liking (Emax) Completer Population*

- All REL-1017 doses including 150 mg (6x therapeutic dose and MTD) were statistically different from IV ketamine 0.5 mg/Kg (p<0.05)
- All REL-1017 doses including 150 mg (6x therapeutic dose and MTD) were statistically equivalent to placebo (p<0.05)
- Key secondary endpoint results were consistent with primary endpoint

*Statistical analysis was performed on the Completer Population which includes all patients who completed all treatments.

MTD = Maximum tolerated dose; IV = Intravenous, Source: Relmada data on file.

Of all all and the states

Exploratory Endpoint – "Drug Liking at This Moment" [Emax] Dextromethorphan, Completer Population

Dextromethorphan vs. REL-1017					
Treatment 10	Treatment 2	P-value			
Dextromethorphan 300 mg	REL-1017 25 mg	<0.001			
Dextromethorphan 300 mg	REL-1017 75 mg	<0.001			
Dextromethorphan 300 mg	REL-1017 150 mg	<0.002			

Emax for all REL-1017 doses is statistically lower compared to dextromethorphan (p<0.05)

Dextromethorphan vs. Ketamine

Treatment 1	Treatment 2	P-value
Dextromethorphan 300 mg	Ketamine 0.5 mg/ Kg	<0.001

Emax for dextromethorphan was statistically lower compared to ketamine (p<0.05)

Dextromethorphan vs. Placebo

Treatment 1	Treatment 2	P-value
Dextromethorphan 300 mg	Placebo	0.001

Emax for dextromethorphan was statistically higher compared to placebo (p<0.05)

SD = Standard Deviation; SE = Standard Error; IV = intravenous Source: Relmada data on file.

Exploratory Endpoint – "Drug Liking at This Moment" [Emax] Dextromethorphan, Completer Population

- Emax for "drug liking at this moment" for dextromethorphan 300 mg was statistically lower compared to ketamine (p<0.05)
- Emax for "drug liking at this moment" for dextromethorphan 300 mg was statistically higher compared to placebo (p<0.05)
- Emax for" drug liking at this moment" for all REL-1017 doses was statistically lower compared to dextromethorphan 300 mg (p<0.05)
- In summary, Emax for "drug liking at this moment" for REL-1017 at all doses was statistically equivalent to placebo and was statistically significantly lower compared to dextromethorphan 300 mg

The results of these two human abuse potential studies support the DEA statement below:


"The *d*-isomer lacks significant respiratory depressant action and addiction liability..."

US Drug Enforcement Administration December 2019¹



8

RELIANCE: The Phase 3 Program for REL-1017




REL-1017 Phase 3 Program for the Treatment of MDD

 Reliance I Reliance II 	 Two sister two-arm, placebo-controlled pivotal studies as adjunctive treatment for MDD: In MDD patients with inadequate response to 1-3 ADT (n= ~364 per study) Primary Endpoint: Change in MADRS at Day 28 Key Secondary Endpoints: Change in CGI-S score at Day 28 Change in MADRS score at Day 7
→ Reliance III	 Two-arm, placebo-controlled pivotal study as a monotherapy treatment for MDD: In MDD patients with ≤ 1 prior use of ADT for current MDE (n=~364) Primary Endpoint: Change from baseline in MADRS at Day 28 Key Secondary Endpoints: Change in CGI-S score at Day 28 Change in MADRS score at Day 7
→ Reliance oLs	Long-term, open-label safety study: Patients continuing from RELIANCE I, II & III Patients new to REL-1017

MDD = major depressive disorder; ADT = antidepressant treatment ; OLS = open label study; MADRS = Montgomery-Asberg Depression Rating Scale; CGIs = Clinical Global Impression scales; MDE = major depressive episode

Pivotal Phase 3 Trial Design for Adjunctive Therapy






Pivotal Phase 3 Trial Design for Monotherapy

Reliance III

27



MADRS = Montgomery-Asberg Depression Rating Scale; CGIs = Clinical Global Impression scales; MDE = major depressive episode; ADT = antidepressant treatment; QD = once daily; OLS = open label study

Vector open ratio scole o Scole open ratio scole open rat


Relmada Development Programs & Timeline*



MDD = Major Depressive Disorder; OLS = Open Label Study *Subject to FDA feedback **Our fiscal year end is December 31. The periods referred to in this slide are calendar years and quarters

B

Neuroplastogen™ Program



We have a pipeline of molecules with neural plasticity modulating activity for the treatment of CNS disorders

Novel esmethadone derivatives

We have synthesized a series of novel esmethadone derivatives with NMDAR regulating activity. We are in the process of selecting the most promising candidates for advancing their development in the treatment of CNS disorders


Novel psilocybin formulation and novel psilocybin derivatives

We are developing a novel psilocybin formulation and we are synthetizing psilocybin derivatives with promising activity for the treatment of CNS disorders

CNS = Central Nervous System; NMDAR = N-methyl-D-aspartate receptor

8

Corporate Information



Financial Overview



* Does not include \$162.2 million net proceeds from an equity offering which closed on 12/14/2021 **As converted share count of 25.8 MM share as of 9/30/2021 and does not include 10.1 million shares from an equity offering which closed on 12/14/2021

33

Investment Highlights

Focus on CNS diseases and Lead Program in **Major Depressive** Disorder (MDD)

Highly Compelling Lead Product Opportunity in **REL-1017**

 REL-1017, lead candidate, is in Phase 3 for depression, a leading cause of disability worldwide1 CNS focus, with expertise in developing novel therapeutics that show potential for neuroplasticity . 50%-66% of patients with depression do not fully recover on an antidepressant medication²

- · Standard anti-depressants can take 2-8 weeks to work and have significant side-effects
- Novel MOA with successful Phase 2 trial in adjunctive MDD that showed statistically significant. robust, rapid, and sustained anti-depressant effects with favorable safety and tolerability profile³
- Phase 3 program underway following successful end of Phase 2 Meeting with the FDA
- Fast track designation from FDA
- Strong intellectual property position around REL-1017 with expirations through the mid/late-2030s .

Key Catalysts Expected Over Next 3-18 Months

- 2Q22 Completion of the monotherapy MDD trial
- 2H22 Completion of RELIANCE I and RELIANCE II adjunctive MDD trials
- 2H22 Completion of RELIANCE OLS (Long-term, Open-label study in MDD)

CNS= Central Nervous System;; MDD = major depressive disorder; MOA = mechanism of action **Our fiscal year end is December 31. The periods referred to in this slide are calendar years and quarters. 1. WHO Depression Fact Sheet; 2. Al-Harbi K S. 2012 *Patient Preference and Adherence*; 3. . Fava et al. Rapid and Sustained Antidepressant Effects of REL-1017 (dextromethadone) as an Adjunctive Treatment for Major Depressive Disorder: A. Phase 2. Thai. 2021. Poster presented at. American Psychiatric Association Annual Meeting.